Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.90
-0.05 (-0.19%)
At close: May 22, 2026, 4:00 PM EDT
25.93
+0.03 (0.12%)
Pre-market: May 26, 2026, 4:34 AM EDT
Pfizer Revenue
Pfizer had revenue of $14.45B in the quarter ending March 29, 2026, with 5.37% growth. This brings the company's revenue in the last twelve months to $63.32B, up 1.36% year-over-year. In the year 2025, Pfizer had annual revenue of $62.58B, down -1.65%.
Revenue (ttm)
$63.32B
Revenue Growth
+1.36%
P/S Ratio
2.33
Revenue / Employee
$844,200
Employees
75,000
Market Cap
147.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.58B | -1.05B | -1.65% |
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | 15.90B | 32.26% |
| Dec 31, 2009 | 49.27B | 973.00M | 2.01% |
| Dec 31, 2008 | 48.30B | -122.00M | -0.25% |
| Dec 31, 2007 | 48.42B | 47.00M | 0.10% |
| Dec 31, 2006 | 48.37B | 966.00M | 2.04% |
| Dec 31, 2005 | 47.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
PFE News
- 5 days ago - Moderately bullish activity in Pfizer with shares up 0.41% - TheFly
- 5 days ago - Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer - Business Wire
- 5 days ago - Pfizer announces pneumococcal conjugate vaccine candidate data - TheFly
- 5 days ago - Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial - Reuters
- 5 days ago - Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results - Business Wire
- 7 days ago - PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’ - TipRanks
- 7 days ago - Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 - PRNewsWire
- 11 days ago - Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch - Barrons